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Abstract
The protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene located
on chromosomes 1p 13.3–13 encodes a lymphoid-specific tyrosine phosphatase
(Lyp) which is involved in autoimmunity by preventing spontaneous T-cell activa-
tion and T-cell development and inactivating T-cell receptor-associated kinases and
their substrates. Several single nucleotide polymorphisms (SNPs) have been identi-
fied in PTPN22, but only one PTPN22 C1858T has been intensively studied in
relation to autoimmune diseases. The PTPN22 C1858T functional polymorphism is a
strong non-HLA risk factor for several autoimmune diseases and considered to play
an important role in etiology of diseases due to significant production of autoanti-
bodies. However, available literature on PTPN22 C1858T polymorphism and auto-
immune diseases shows inconsistencies and ethnic variations. Therefore, further
genetic studies on patients suffering from various autoimmune diseases from dif-
ferent ethnicities and PTPN22 gene polymorphisms are expected to help better
understand the pathogenesis and will contribute to the development of more
targeted therapies and biomarkers.
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1. Introduction
Genetic polymorphisms are variations in DNA found in 1% or more of the
population which may alter the structure and function of protein through a single
nucleotide base substitution in a gene’s coding region. It may alter the gene expres-
sion either by affecting mRNA stability when occurring in a gene’s 30-untranslated
region or by changing transcription factor binding when occurring in the 50-pro-
moter region. A polymorphism does not have any effect on the protein product
when it occurs within DNA regions that are not involved in gene transcription or
translation but serves as the basis for genetic linkage analysis [1].
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The information on genetic polymorphisms facilitates to explain pathologic
mechanisms and help in identifying individuals at risk. It also helps us to find novel
targets for drug treatment. The protein tyrosine phosphatase non-receptor type 22
(PTPN22) gene is an important predisposing gene for human autoimmune diseases.
The alterations in PTPN22 render a person susceptible and lead to the development
of several autoimmune diseases. Many single nucleotide polymorphisms (SNPs)
have been identified in PTPN22, but only one non-synonymous SNP has been
intensively studied in relation to autoimmune diseases. This SNP C1858T
(rs2476601) in exon 14 of the PTPN22 gene has been associated with a number of
autoimmune diseases and considered as a risk factor due to significant production
of autoantibodies [2, 3].
The PTPN22 C1858T variant has been studied in autoimmune diseases such as
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes
mellitus, juvenile idiopathic arthritis (JIA), inflammatory bowel disease (IBD)
including Crohn’s disease (CD) and ulcerative colitis (UC), antineutrophil
cytoplasmic antibody (ANCA)-associated vasculitis, vitiligo, systemic sclerosis
(SSc), Graves’ disease (GD), myasthenia gravis (MG), Addison’s disease,
psoriasis, psoriatic arthritis (PsA), Behcet’s disease (BD), endometriosis,
autoimmune thyroid disease (AITD), giant cell arteritis (GCA), alopecia areata
(AA), and Sjögren’s syndrome. The association of PTPN22 C1858T genetic poly-
morphism is very significant and noteworthy in some autoimmune diseases, while
in other it is less significant [3]. However, available literature on PTPN22 C1858T
polymorphism and autoimmune diseases shows inconsistencies and ethnic
variations exist.
2. PTPN22 gene
PTPN22 gene is located on chromosomes 1p13.3–p13.1 and encodes a lymphoid-
specific tyrosine phosphatase (Lyp). Lyp is an intracellular protein tyrosine phos-
phatase, bound to the SH3 domain of the C-terminal Src kinase (Csk) through a
proline-rich motif. It is believed to suppress kinases mediating T-cell activation [4].
Lyp plays an important role in B-cell signaling, besides functioning as a negative
regulator of T cells. It works in signaling cascade at various levels and targets several
signaling intermediates involved in T-cell receptor signaling [5, 6]. After HLA,
PTPN22 gene is the second-most important predisposing gene for human autoim-
mune diseases.
The minor allele 1858T in the PTPN22 locus has a strong and consistent genetic
association with autoimmune diseases. In PTPN22 C1858T (rs2476601), cytosine
changes to thymidine at nucleotide 1858, resulting in an amino acid change from
arginine to tryptophan at codon 620 (R620W), located in the polyproline-binding
motif P1 [7, 8]. Yet there is no consensus whether C1858T polymorphism is a gain-
or loss-of-function variant. The C1858T has been reported as a susceptibility locus
associated with several autoimmune diseases. It was first reported in type 1 diabetes
mellitus (T1DM) [7].
PTPN22 C1858T polymorphism has been suggested to increase Lyp protein
activity which in turn inhibits T-cell signaling and results in a failure to delete
autoreactive T cells during thymic selection. The association of this polymorphism
is restricted to disorders that have a strong autoantibody component as it results in
immune responses against autoantigens [8].
With the advent of new genotyping and molecular biology techniques, a huge
amount of data are available for analysis. A large number of genes associated with
diseases have been identified by the GWAS, candidate gene, and epidemiological
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studies. Therefore, the focus should be on the way genetic associations are reported.
Even in the overlapping meta-analyses on the same topic, the limitations such as
inclusion and exclusion criteria and number of included studies result in consis-
tency of association results of genes, although the meta-analysis has been consid-
ered as a powerful approach to identify true-positive association of genes with
disease.
The PTPN22 C1858T variant has been studied in several autoimmune or
autoimmunity-related diseases in different ethnic populations worldwide.
3. Autoimmune diseases
Autoimmune diseases are pathological conditions identified by abnormal
autoimmune responses and characterized by autoantibodies and T-cell responses to
self-molecules by immune system reactivity. Human autoimmune diseases occur
frequently (affecting in aggregate more than 5% of the population worldwide)
and impose a significant burden of morbidity and mortality on the human
population [9].
The etiology of autoimmune diseases involves both genetic and environmental
factors. Familial clustering is known in autoimmune diseases with higher rate of
concordance in monozygotic twins as compared to dizygotic twins [10–12]. Most
autoimmune diseases are multigenic, with multiple susceptibility genes working in
concert to produce the disease; however, a few autoimmune diseases are caused by
mutations in a single gene. Even in such cases other genes modify the severity of
disease. On the other hand, some individuals with these mutations do not manifest
the disease.
The genetic polymorphisms also occur in normal population and are compatible
with a normal immune function. However, when these polymorphisms occur with
Population Case/controls Genotype/allele/polymorphism Association References
Mexican 187/223 CT Susceptible [20]
Indian (Tamils) 264/264 CT Susceptible [25]
Indian (Gujarati) 126/140 C1858T No association [32]
English 165/304 C1858T Susceptible [29]
Romanian – T-allele Susceptible [30]
European*
Asian
2094/3613 T-allele
T-allele
Susceptible
No association
[28]
Turkish 107/112 C1858T No association [27]
European*
Asian
1800/3269 T-allele
T-allele
Susceptible
No association
[26]
Jordanian 55/85 C1858T No association [33]
Egyptian 100/120 C1858T No association [34]
Caucasian#
European
1514/2813 C1858T Susceptible [31]
*Meta-analysis.
#Genome-wide association study.
Table 1.
Association of PTPN22 C1858T polymorphism with vitiligo susceptibility.
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other susceptibility genes, they develop autoimmunity [13, 14]. The extent of risk is
not same for all such genes, and some of the genes confer a much higher level of risk
than others [9].
The results of various association studies of PTPN22 C1858T variant with some
of the autoimmune diseases are summarized in Tables 1–18.
Population Case/controls Genotype/allele/polymorphism Association References
Mexican 64/225 T-allele Susceptible [41]
Belgian-German 435/628 C1858T Susceptible [39]
English 196/507 C1858T Susceptible [38]
Mixed* 1129/1702 T and CT Susceptible [43]
Mixed* 365/173 C1858T Susceptible [42]
Egyptian 103/100 CT, TT Susceptible [40]
Iranian 69/69 T-allele No association [44]
*Meta-analysis.
Table 2.
Association of PYPN22 C1858T polymorphism with alopecia susceptibility.
Population Case/controls Genotype/allele/polymorphism Association References
Saudi 106/200 T-allele, CT Susceptible [53]
German 375 + 418/376 + 561 C1858T No association [57]
English 647/566 C1858T No association [58]
Caucasian 1146 C1858T No association [59]
Mixed* 3334/5753 T-allele No association [56]
Mixed* 1448/1385 C1858T No association [55]
Cretan (Greek) 173/348 T-allele No association [60]
*Meta-analysis.
Table 3.
Association of PTPN22 C1858T polymorphism with psoriasis susceptibility.
Population Case/controls Genotype/allele/polymorphism Association References
Toronto (admixed) 207/199 T-allele Susceptible [61]
Swedish 291/725 T-allele Susceptible [62]
Mixed# 1177/2155 C1858T Susceptible [63]
UK 455/595 C1858T No association [65]
Newfoundland 238/149 T-allele No association [61]
German 375/376 T-allele No association [66]
#Genome-wide association study.
Table 4.
Association of PTPN22 C1858T polymorphism with psoriatic arthritis susceptibility.
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Population Case/
controls
Genotype/allele/
polymorphism
Association References
American (European
ancestry)
647/751 C1858T Susceptible [67]
Australian 324/568 C1858T Susceptible [70]
Australian 413/690
1608/9284
C1858T Susceptible in
females
[71]
Greek 128/221 C1858T Susceptible [73]
Egyptian 60/40 T-allele Susceptible [75]
UK 661/595 C1858T Susceptible [65]
Czechs 130/400 T-allele Susceptible [72]
European 809/3535 C1858T Susceptible [69]
Norwegian 320/555 C1858T Susceptible [74]
Mixed* 4552/10,161 C1858T Susceptible [77]
Mixed* 4238/6012 C1858T Susceptible [76]
Finish 230 T-allele No association [78]
Hungarian 150/200 T-allele No association [79]
*Meta-analysis.
Table 5.
Association of PTPN22 C1858T polymorphism with juvenile idiopathic arthritis susceptibility.
Population Case/controls Genotype/allele/polymorphism Association References
Spanish 826/1036 T-allele Susceptible [96]
Italian 396/477 T-allele Susceptible [92]
Turkish 323/426 C1858T Susceptible [97]
Colombian 298/308 T-allele Susceptible [86]
Colombian 413/434 T-allele Susceptible [87]
Egyptian 150/150 T-allele Susceptible [89]
Egyptian 394/398 C1858T Susceptible [90]
Egyptian 112/122 T-allele Susceptible [88]
Egyptian 100/114 C1858T No association [100]
Algerian 110/197 C1858T Susceptible [85]
Mexican 315/315 C1858T Susceptible [95]
Mexican 364/387 C1858T Susceptible [94]
Mexican 309/347 T-allele Susceptible [93]
UK 886/595 C1858T Susceptible [65]
Iranian 120/120 C1858T Susceptible [91]
Iranian 120/120 T-allele Susceptible [84]
Iranian 405/467 C1858T No association [101]
Chinese Han 358/564 C1858T No association [99]
Chinese-Yunnan 192/288 C1858T No association [98]
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Population Case/controls Genotype/allele/polymorphism Association References
Caucasian*
Asian*
27,205/27,677 C1858T
C1858T
Susceptible
No association
[103]
European*
Asian and African
29 studies C1858T
C1858T
Susceptible
No association
[104]
Mixed* 11,727/12,640 T-allele Susceptible [105]
Mixed* 3209/3692 C1858T Susceptible [106]
Mixed* 20,344/21,828 C1858T Susceptible [76]
Mixed* 13 studies T-allele Susceptible [107]
Mixed* 17,961/18,611 C1858T Susceptible [102]
Mixed* 34 studies C1858T Susceptible [108]
Mixed* 36 studies T-allele Susceptible [2]
*Meta-analysis.
Table 6.
Association of PTPN22 C1858T polymorphism with RA susceptibility.
Population Case/
controls
Genotype/allele/
polymorphism
Association References
Spanish 338/1036 T-allele Susceptible [96]
Swedish 571/1042 C1858T Susceptible [120]
American 525/1961 C1858T Susceptible [116]
Crete 328/427 C1858T Susceptible [119]
Colombian 94/434 T-allele Susceptible [87]
Colombian 143/308 T-allele Susceptible [86]
Polish 135/201 CT, T-allele Susceptible [122]
Polish 150/300 C1858T Susceptible [121]
Mixed* 6 studies T-allele susceptible [107]
Mixed* 772/1092 C1858T Susceptible [126]
Mixed* 9120/11724 C1858T Susceptible [128]
Mixed* 11 studies CT, TT Susceptible [125]
Mixed* 14 studies T-allele Susceptible [2]
Mixed* 3868/7458 T-allele, TT Susceptible [127]
European-Americans 3936/3491 C1858T Susceptible [118]
Hispanics 1492/807 C1858T No association [118]
African-Americans 1527/1811 C1858T No association [118]
Asians 1265/1260 C1858T No association [118]
Egyptian 170/241 C1858T Susceptible [124]
Egyptian 40/20 CT Susceptible [123]
Egyptian 60/60 C1858T No association [133]
European-American 1680/1467 T-allele Susceptible [117]
Mexican 500/355 T-allele Susceptible [134]
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Population Case/
controls
Genotype/allele/
polymorphism
Association References
Mexican mestizos 150/150 C1858T No association [130]
Turkish 158/155 C1858T No association [131]
Turkish 137/160 C1858T No association [132]
Chinese Han 713/672 C1858T No association [99]
Chinese 40/20 C1858T No association [129]
*Meta-analysis.
Table 7.
Association of PTPN22 C1858T polymorphism with SLE susceptibility.
Population Case/controls Genotype/allele/polymorphism Association References
Egyptian 60/60 C1858T Susceptible [133]
German 140/100 T-allele Susceptible [138]
Mixed* 3764/3328 C1858T Susceptible [139]
Japanese 456/221 T-allele No association [143]
Japanese 334/179 C1858T No association [144]
Korean 212/225 T-allele No association [145]
Polish 149/200 C1858T No association [147]
Jordanian Arab 204/2016 C1858T No association [146]
*Meta-analysis.
Table 8.
Association of PTPN22 C1858T polymorphism with AITD susceptibility.
Population Case/controls Genotype/allele/polymorphism Association References
Latin-American 83/336 C1858T Susceptible [148]
Polish 166/154 C1858T Susceptible [149]
Polish 290/310 T-allele Susceptible [150]
Polish 735/1216 C1858T No association [154]
English 768/768 C1858T Susceptible [140]
English 549/429 C1858T Susceptible [151]
English 901/833 C1858T Susceptible [152]
Mixed* 3 studies T-allele Susceptible [2]
Mixed* 3764/3328 C1858T Susceptible [139]
Indian Kashmiri 135/150 C1858T No association [155]
Chinese Han# 5904/5866 C1858T No association [153]
*Meta-analysis.
#Genome-wide association study.
Table 9.
Association of PTPN22 C1858T polymorphism with Graves’ disease susceptibility.
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Population Case/controls Genotype/allele/
polymorphism
Association Reference
Tunisian 164/100 C1858T Susceptible [163]
Moroccan 195/311 C1858T No association [167]
Spanish 1903CD, 1677UC/
3111
C1858T Protective to CD [165]
New
Zealanders
315/4081 C1858T No association with
CD
[168]
Czech 345/501 C1858T No association [169]
Canadian 455/190 C1858T No association with
CD
[170]
Canadian 249/207 T-allele No association with
CD
[171]
British 514/374 C1858T No association [172]
Spanish 1113/812 C1858T No association [173]
German 146 C1858T No association with
CD
[174]
Mixed* 8182/13356 C1858T Susceptible to CD [164]
Meta-analysis C1858T Protective to CD [2]
Italian 649/256 C1858T No association [175]
*Meta-analysis.
Table 10.
Association of PTPN22 C1858T polymorphism with IBD (CD + UC) susceptibility.
Population Case/controls Genotype/allele/
polymorphism
Association References
Saudi 372/372 T-allele Susceptible [184]
German 220/239 C1858T Susceptible [185]
Egyptian 150/165 T-allele Susceptible [186]
Egyptian 120/120 T-allele Susceptible [187]
Kuwaiti Arabs 253/2014 T-allele Susceptible [188]
Chinese 202/240 C1858T Susceptible [189]
Chinese 364/719 C1858T No association [178]
Brazilian 612/792 C1858T Susceptible [190]
Brazilian 205/308 C1858T Susceptible [191]
Polish 215/236 C1858T Susceptible [192]
Polish 147/327 C1858T Susceptible [193]
Russian 27/62 families C1858T Susceptible [194]
Croatian 102/193 T-allele Susceptible [195]
Caucasian 140/100 T-allele Susceptible [138]
Caucasian 8677 C1858T Susceptible [196]
Caucasian 113 C1858T Susceptible [197]
Czechs 372/400 T-allele Susceptible [72]
Iranian (Azeri) 160/271 T-allele Susceptible [72]
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Population Case/controls Genotype/allele/
polymorphism
Association References
Iranian 99/100 C1858T Susceptible [84]
Iranian 144/197 C1858T No association [181]
Estonian 170/230 T-allele Susceptible [198]
Italian 271/89 C1858T Susceptible [199]
Spanish 316/554 T-allele Susceptible [200]
Colorado 753/662 CT, TT Susceptible [201]
Colombian 110/308 T-allele Susceptible [86]
Colombian 197 families C1858T Susceptible [202]
International
children
257 C1858T Associated with
proinsulin levels
[203]
Mixed* 6 studies C1858T Susceptible [107]
Mixed* 19,495/25,341 C1858T Susceptible [204]
Mixed* 22,485/35,292 C1858T Susceptible in
Caucasian
[205]
Mixed* 11 studies T-allele Susceptible in European [206]
Mixed* 16,240/17,997 C1858T Susceptible [207]
Mixed* 8869/20,829 C1858T Susceptible [208]
Mixed* 10 studies C1858T Susceptible [209]
Indian 145/210 T-allele Susceptible [210]
Indian 129/109 C1858T No association [180]
Greek 130/135 C1858T No association [179]
*Meta-analysis.
Table 11.
Association of PTPN22 C1858T polymorphism with T1DM susceptibility.
Population Case/
controls
Genotype/allele/
polymorphism
Association References
French 659/504 T-allele Susceptible [216]
French 121/103 C1858T No
association
[218]
Mixed White, Black,
Hispanic
1120/716 C1858T Susceptible [217]
Caucasian 3422/3638 C1858T Susceptible [214]
Mixed* 4367/4771 C1858T Susceptible [107]
Columbian 101/434 T-allele No
association
[87]
Spanish 54/55 C1858T No
association
[219]
*Meta-analysis.
Table 12.
Association of PTPN22 C1858T polymorphism with systemic sclerosis susceptibility.
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Population Case/controls Genotype/allele/polymorphism Association References
Swedish 409/1557 C1858T Susceptible [228]
German 125/301 C1858T Susceptible [229]
European 649/ C1858T Susceptible [230]
Mixed* 2802/3730 C1858T Susceptible [221]
Hungarian, German 282/379 T-allele Susceptible [231]
French 470/296 C1858T Susceptible [232]
European# 532/2128 C1858T Susceptible [235]
Chinese 79/50 C1858T No association [2]
Turkish 416/293 C1858T No association [234]
Italian 356/439 C1858T No association [233]
*Meta-analysis.
#Genome-wide association study.
Table 13.
Association of PTPN22 C1858T polymorphism with myasthenia gravis susceptibility.
Population Case/controls Genotype/allele/polymorphism Association References
Spanish 404/1517 C1858T No association [243]
Turkish 134/177 C1858T No association [242]
UK and Middle East 270/203 C1858T Protective [241]
Mixed* 1922/11,505 C1858T No association [76]
*Meta-analysis.
Table 14.
Association of PTPN22 (C1858T) polymorphism with Behcet’s disease susceptibility.
Population Case/controls Genotype/allele/polymorphism Association Reference
Italian 132/232 C1858T Susceptible [252]
Italian 132/359 T-allele Susceptible [253]
Italian 130/250 C1858T Susceptible [254]
Brazilian 140/180 C1858T Susceptible [255]
Mixed* 971/1181 T-allele Susceptible [246]
Polish 171/310 C1858T No association [248]
*Meta-analysis.
Table 15.
Association of PTPN22 C1858T polymorphism with endometriosis susceptibility.
Population Case/controls Genotype/allele/polymorphism Association References
German 199/399 T-allele Susceptible [259]
British 641/9115 C1858T Susceptible [260]
Italian 344/945 C1858T Susceptible [261]
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4. Vitiligo
Vitiligo is an acquired, autoimmune skin disorder characterized by melanocyte
loss resulting into progressive depigmentation of the skin and hair [15, 16]. The
prevalence of vitiligo varies considerably with ethnicity and it affects 0.1–2% of the
population worldwide [15, 17]. Vitiligo is associated with an elevated risk of several
other autoimmune diseases [18–20].
Vitiligo commonly shows familial aggregation and multifactorial mode of inher-
itance. It is a polygenic disease, and several genes related to autoimmunity have
been reported to be associated with the pathogenesis of vitiligo [20–25].
Various published reports on PTPN22 C1858T polymorphism support the asso-
ciation of the T-allele and vitiligo susceptibility in different ethnic populations
(Table 1). However, available literature on the PTPN22 C1858T polymorphism and
Population Case/
Controls
Genotype/allele/
polymorphism
Association References
Spanish 95/229 C1858T No
association
[263]
Spanish, German,
Norwegian
911/8136 C1858T Susceptible [265]
European 1651/
15,306
C1858T Susceptible [266]
Australian 209/455 T-allele Susceptible [267]
Table 17.
Association of PTPN22 C1858T polymorphism with giant cell arteritis susceptibility.
Population Case/controls Genotype/allele/polymorphism Association References
Norwegian 332/990 T-allele Susceptible [269]
UK and Polish 338/665 T-allele Susceptible [270]
English 104/429 C1858T Susceptible [151]
Mixed* 6 studies T-allele Susceptible [2]
German 121/239 C1858T No association [185]
Mixed* 2 studies C1858T No association [107]
*Meta-analysis.
Table 18.
Association of PTPN22 C1858T polymorphism with Addison’s disease susceptibility.
Population Case/controls Genotype/allele/polymorphism Association References
Mixed* 1399/9934 C1858T Susceptible in White [262]
Mixed* 1922/11,505 C1858T Susceptible [76]
*Meta-analysis.
Table 16.
Association of PTPN22 C1858T polymorphism with antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitis susceptibility.
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vitiligo susceptibility is inconsistent [25–28]. It has been reported to be a risk factor
for vitiligo in English, Romanian, North American, Mexican, and South Indian
Tamil populations [20, 25, 29, 30]. PTPN22 C1858T polymorphism is strongly
associated with vitiligo susceptibility in Saudis also [in press]. A genome-wide
association study indicates that PTPN22 C1858T is associated with vitiligo in
European-derived white patients [Jin et al. 2010]. A meta-analysis utilizing data
from different ethnicities shows an association of PTPN22 C1858T with vitiligo in
European but not in Asian population [28].
In contrast, no significant association of PTPN22 C1858T polymorphism with
susceptibility to generalized vitiligo was found in Indian Gujarat population, Jorda-
nian, Egyptian female, and Turkish population [27, 32–34]. Available literature
shows that the variant of PTPN22 C1858T is responsible for increased risk of vitiligo
in Caucasian patients; however, among non-Caucasians/Asians, inconsistency exits,
and even the two populations of same country differ in association of PTPN22
C1858T with vitiligo indicating the role of ethnicity. The heterozygous CT genotype
of the PTPN22 C1858T has a strong association with non-segmental vitiligo in South
Indian Tamils, while there is no association of this polymorphism in Indian Gujarat
population [25, 32]. This difference in the results of this polymorphism in Asians or
non-Caucasians can be attributed to ethnic differences.
5. Alopecia areata (AA)
AA is a dermatological condition in which hair is lost from certain or all areas of
the body, typically from certain areas of the scalp, more frequent in young ones
[35]. The characteristic feature of AA is circular or oval bald spots which may
progress and spread to the entire scalp (alopecia totalis) or entire body (alopecia
universalis). Sometimes hair loss is localized to the sides and lower back of the scalp
which is known as alopecia ophiasis [36]. The prevalence of AA in the general
population varies between 0.1 and 6.9% depending on the ethnic group [37].
Alopecia areata is an autoimmune disease mediated by T cells to the hair folli-
cles. There are enough evidences indicating that AA is a complex multigenetic trait
with components of inherited predisposition. Molecular biology studies have led to
the identification of a number of candidate genes in humans that confer suscepti-
bility to AA. Recently, PTPN22 gene has been reported to be an additional immu-
noregulatory gene associated with AA. PTPN22 C1858T polymorphism has been
associated with susceptibility of AA in Belgian, English, Egyptian, German, and
Mexican populations (Table 2) [38–43]. Two meta-analyses have also indicated an
association with AA susceptibility [42, 43]. However, no association of PTPN22
C1858T has been found in Iranian patients [44].
6. Psoriasis
Psoriasis is a chronic, complex autoimmune disease with characteristic reddish
patches covered by silvery-white scales. It affects approximately 120–180 million
people worldwide [45]. The prevalence of psoriasis varies significantly depending
mainly on race, geographical location, genetics, environmental factors, and ethnic-
ity [46–50].
The etiology of psoriasis involves both genetic and environmental factors indi-
cating a multifactorial nature. Moreover, a number of characteristic features of
psoriasis are also found in other autoimmune diseases indicating a common
etiology [51, 52].
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Though the pathogenesis of psoriasis and comorbidities has been studied at the
molecular level and a number of gene loci have been associated with susceptibility/
severity of psoriasis [50–53], genes identified till date to be associated with it do not
fully account for it. Psoriasis is highly heritable, and it has been suggested in several
association studies that skin barrier function, innate and adaptive immunity, and
gene-gene and gene-environment interactions are involved in the pathogenesis of
psoriasis [52].
Recently an association of T-allele of the PTPN22 C1858T with susceptibility to
psoriasis in Saudi population was reported (Table 3) [53]. Earlier it has been
suggested that PTPN22 may be among the true psoriasis susceptibility risk genes
[54]. However, another study analyzed 15 SNPs from 7 putative psoriasis-risk genes
and could not find any significant association of PTPN22 C1858T polymorphism
with psoriasis. On the other hand, they found a significant association with another
polymorphism (rs3789604) in PTPN22 gene and suggested that PTPN22 is one of
the significant risk genes for psoriasis [55]. Chen and Chang [56] reported a strong
association of PTPN22 + 1858T allele with PsA but no association with psoriasis and
suggested that attention should be given to the studies dealing with gene-
environment interaction besides keeping in consideration the clinical heterogeneity
of the disease and population stratification.
Earlier Hüffmeier et al. [57] found gender variations in susceptibility of PTPN22
(+1858T allele) with psoriasis and suggested that other susceptibility locus/loci
within noncoding regions of PTPN22 or its proximity might exist and act indepen-
dently as a risk factor. They excluded the direct link of T-allele in psoriasis suscep-
tibility in German psoriasis patients.
7. Psoriatic arthritis
PsA is a chronic inflammatory arthritis associated with psoriasis. PsA is a chronic
skin and joint condition that considerably affects patient’s quality of life. PsA is a
complex disease with environmental and genetic risk factors contributing to it.
Several studies have demonstrated different associations of genetic polymorphisms
in the pathogenic process of PsA.
PTPN22 C1858T polymorphism has also been strongly associated with PsA
(Table 4) in Toronto admix and Swedish population [61, 62]. Several non-HLA loci
including PTPN22 have been suggested to affect the susceptibility to PsA [63, 64].
A complete genetic overlap has been suggested between psoriasis and PsA suscep-
tibility loci as about a third of people who have psoriasis gets PsA. It has been
noticed that subjects with severe psoriasis have a greater chance of getting PsA and
about 40% of patients with PsA have relatives with it or with psoriasis, while other
earlier studies reported no association of PTPN22 C1858T polymorphism and PsA in
Newfoundland, the UK, and German Caucasian [57, 61, 65]. Though no significant
differences were observed in allele distribution with different manifestations of
disease, there is gender difference, and male PsA patients has higher frequency of
T-allele than in the subgroup of female patients [66].
8. Juvenile idiopathic arthritis
JIA is the most common inflammatory disease of the joints in children. Its
etiology is complex and involves both genetic and environmental factors. It has
been suggested that genetic factors play a significant role in the susceptibility to JIA
[67]. While associations between JIA and variants in HLA are well established,
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non-HLA genetic variants also play a role in JIA susceptibility and have increasingly
been identified by genome-wide and candidate gene studies [68, 69]. Many of the
genetic associations have been confirmed recently by the International JIA
Immunochip consortium, and several novel loci have also been identified showing a
genome-wide association.
Several reports indicate that PTPN22 C1858T polymorphism has been consis-
tently associated with JIA (Table 5). PTPN22 C1858T polymorphism is associated
with JIA in Australians [70, 71], Americans of European ancestry [67], Czech [72],
Europeans [69], Greek [73], Norwegians [74], UK population [65], and Egyptians
[75]. Two separate meta-analyses also indicated that PTPN22 C1858T is associated
with susceptibility to JIA [76, 77]. However, it is not associated with JIA in Finish
and Hungarian patients [78, 79]. These variations may be due to ethnic variations;
however, methodological error in genotyping cannot be ruled out.
9. Rheumatoid arthritis
RA is a chronic autoimmune disorder of bone joints caused by the complex
interplay between several factors like body physiology and the environment with
genetic background [80, 81]. RA is characterized by synovial inflammation, hyper-
plasia, cartilage and bone destruction, autoantibody production (rheumatoid fac-
tor), anticyclic citrullinated peptide (CCP), and the decreased quality of life [82].
Its prevalence is approximately 0.51% worldwide and afflicts people of all races.
RA shares a number of pathogenic mechanisms with other autoimmune disor-
ders. More than 100 loci have been associated with RA as shown in a meta-analysis
of GWAS. Out of these majority (97%) are located in the noncoding region, and the
remaining 3% are in various non-HLA genes including PTPN22 (Trp620Arg) [83].
Several studies have been performed on the association of PTPN22 C1858T
variants with RA susceptibility in different ethnic populations (Table 6). Various
studies have demonstrated that allelic heterogeneity distribution has an increasing
north-south gradient in the frequencies of the 1858T alleles in different European
populations [84]. PTPN22 C1858T polymorphism has been associated with suscep-
tibility to RA in Algerian [85], Colombian [86, 87], Egyptian [88–90], Iranian
[84, 91], Italian [92], Mexican [93–95], Spanish [96], Turkish [97], and UK Cauca-
sian populations [65].
On the other hand, some studies reported that it is not associated with RA in
Chinese [98, 99], Egyptian [100], and Iranian populations [101]. A number of
meta-analyses have also shown that T-allele of PTPN22 C1858T is associated with
RA susceptibility in Caucasians but not in Asians and Africans (Table 6) [102–104].
The different allele frequency of T-allele is very important in determining the
population attributable risk of this allele for the autoimmune diseases in different
populations. It also affects any suggested screening or predictive testing protocol for
these diseases [101]. The absence of this association in Asians undermines the
importance of this locus as a susceptibility locus for the RA and other autoimmune
diseases.
10. Systemic lupus erythematosus
SLE is a heterogeneous autoimmune inflammatory disease characterized by loss
of self-tolerance with hyperactivation of autoreactive T and B cells with a predom-
inance of Th2 inflammatory response [109]. The SLE incidence rate varies from 1 to
10 per 100,000 person/years, and the prevalence varies from 20 to 70 per 100,000
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persons. SLE affects more than 300,000 people in the United States (USA) and
millions worldwide [110]. It is characterized by multisystem involvement, autoan-
tibody formation, and dysregulation of the complement system. The onset of SLE is
postulated to be triggered by environmental and hormonal factors in genetically
susceptible individuals [111, 112].
The genetic contribution to the development of SLE is considerably high, which
is estimated to be 66% of heritability in twin studies. Genome-wide association
studies (GWASs) have greatly improved our understanding of the genetic basis of
SLE [113]. A high-density SNP analysis has identified and facilitated to focus on
disease-associated loci where patients and healthy controls exhibit different fre-
quencies of trait-associated alleles which are potential disease-causal variants or
their proxies [113]. To date, about 100 SLE susceptibility loci have been identified,
mostly in European and Asian populations [112], explaining the heritability of SLE
up to around 30% [114, 115]. The highly polygenic etiology of SLE is supported by a
large number of disease-associated loci that have modest effect sizes but surpass the
genome-wide significance threshold for the genetic association with SLE as
reviewed by Kwon et al. [112].
PTPN22 C1858T polymorphism has been associated with the pathogenesis of
SLE in various populations (Table 7). This polymorphism is significantly associated
with susceptibility to SLE in American [116–118], Columbian [86, 87], Crete [119],
Spanish [96], Swedish [120], Polish [121, 122], Egyptian populations [123, 124].
Several meta-analyses also indicated that PTPN22 C1858T polymorphism is
associated with SLE susceptibility [2, 107, 125–128]. On the other hand, it is not
associated with SLE in Asians [118], Chinese [99, 129], Hispanics, African-
Americans [118], Mexican mestizos [130], and Turkish patients [131, 132].
11. Autoimmune thyroid disease
Autoimmune thyroid disease (AITD) is a complex disease which includes GD
and Hashimoto’s thyroiditis (HT). Its susceptibility is influenced by both genetic
and environmental factors. The interaction of specific susceptibility genes and
environmental exposures have been associated with AITD [135]. Both GD and HT
are characterized by the production of thyroid autoantibodies and the invasion of
thyroid lymphocytes. AITD is found in 5% of the general population and is one of
the most prevalent autoimmune diseases. The incidence of GD and HT is influenced
by genetic factors as well as environmental factors including geographical locations
[136]. Approximately 37% of families with AITD exhibit either of these two
disorders [137].
Previous molecular studies on genetic etiology of AITD have expanded the field
of thyroid autoimmunity. Previous studies have shown that PTPT22 C1858T is
associated with AITD [138, 139] (Table 8). Some reports have indicated a positive
correlation [140–142], while others have indicated no correlation between PTPN22
C1858T and AITD in Japanese [143, 144], Korean [145], Jordanian, [146], and
Polish populations [147].
PTPN22 C1858T polymorphism has been associated with GD (Table 9). It is
susceptible to GD in Latin-American [148], Polish [149, 150], and English Cauca-
sian populations [140, 151, 152]. Two separate meta-analyses confirmed the associ-
ation of PTPN22 + 1858C/T polymorphism with Graves’ disease [2, 139]. However,
some reports have indicated no correlation between PTPN22 + 1858C/T and Graves’
disease in Chinese Han, Polish, and Indian Kashmiri populations [153–155].
Jacobson et al. [156] reported that the PTPN22 + 1858C/T is related to the
occurrence of HT. Another variant in PTPN22 gene has been found to be associated
15
The Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22) Gene Polymorphism…
DOI: http://dx.doi.org/10.5772/intechopen.90836
with HT using whole-exome sequencing [157] indicating the role of PTPN22 in
autoimmune thyroid disease. However, the functional mechanism involved in the
association remains to be found out.
12. Inflammatory bowel disease
IBD is a complex, multifactorial, chronic inflammatory disorder of the gastroin-
testinal tract in which immune dysregulation caused by genetic and/or environ-
mental factors plays an important role. IBD refers to two chronic inflammatory
disorders of the gastrointestinal tract: UC and CD.
The IBD is a complex autoimmune disease. Its etiology is characterized by
immune dysregulation caused by genetic and/or environmental factors [158, 159]. A
genetically susceptible person develops IBD as a result of the immunogenic
responses against environmental factors and/or microbes inhabiting the distal ileum
and colon. It is believed that genetic factors contribute significantly to the patho-
genesis of IBD [160–162]. Genome-wide scans performed in patients with IBD have
failed to find a major unique susceptibility locus and have prompted the general
agreement that these diseases are polygenic entities in which several genes may
contribute to susceptibility [162].
Sfar et al. [163] reported an association of PTPN22 C1858T polymorphism with
IBD in Tunisian patients. Recently a meta-analysis utilizing 8182 patients and 13,356
controls indicated that this is associated with CD susceptibility only and there is no
association with UC [164]. No association of PTPN22 C1858T polymorphism with
IBD was found in British, Canadian, Czech, German, Italian, Moroccan, New
Zealander, and Spanish populations (Table 10). Another study on Spanish patients
showed that this polymorphism is protective to CD while there is no association
with UC [165]. A meta-analysis also indicated that PTPN22 C1858T polymorphism
is associated with reduced susceptibility to CD with no association with UC [2].
Despite the association of PTPN22 C1858T SNP with CD and several different
autoimmune disorders, a role for this polymorphism in susceptibility to IBD does
not establish.
Thus, it is plausible that this genetic discrepancy in PTPN22 influences a range
of diseases in which the phenotypic spectrum includes an aberrant or hyperactive
immune response [5, 166]. However, these variations in the association reports of
PTPN22 C1858T polymorphism with IBD may be due to ethnic variations in genetic
makeup of the different populations. It has been suggested that the presence of T-
allele of PTPN22 C1858T makes an individual susceptible to autoimmune diseases
by helping the production of antibodies associated with these diseases, resulting in
the disease development [116].
13. Type 1 diabetes mellitus
Type 1 diabetes is an autoimmune disease in which the insulin-producing cells
are attacked by the body’s defense system resulting in no insulin or very little insulin
production. Although the exact cause of the T1DM is not clear yet, it has been
associated with both genetic and environmental factors. It usually develops in
children or young adults but can affect people of all age group. The patient will die
if there is no access to insulin. Therefore, daily injection of insulin is required to
control the blood glucose levels in patients with T1DM.
The International Diabetes Federation (IDF) has reported that there were 382
million people living with diabetes worldwide in 2013 and this number is expected
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to rise to 592 million by 2035 [176]. Most people with diabetes live in low- and
middle-income countries, where rapid changes in lifestyle have increased the prev-
alence of diabetes, cardiovascular diseases, and cancer, and these countries are
expected to experience the greatest increase in cases of diabetes in the next 20 years.
The global prevalence of diabetes was reported as 8.8% of the world’s population
(95% confidence interval 7.2–11.3%) in 2017, and it is expected to increase to
9.9% in 2045 [177]. At present in every seventh second, someone dies from diabetes
or its complications. Fifty percent of these deaths are under the age of 60 years.
According to a report, 424.9 million people were having diabetes worldwide in
2017 which is expected to increase to 628.6 million people in 2045. The prevalence
of diabetes is continuously increasing since the IDF Diabetes Atlas first was
launched in 2000, and about 50% of the diabetes cases remain undiagnosed espe-
cially in developing countries which is a matter of concern [177].
A positive association between PTPN22 C1858 T polymorphism and susceptibil-
ity to the development of T1DM has been reported in a large number of studies
from several populations (Table 11) with the exception of a few such as a single
study from Chinese [178], Greek [179], Indian [180], and Iranian populations [181]
where no association was found.
The review by Prezioso et al. [182] evaluated the role of the PTPN22 C1858 T in
the prognosis of disease. On the basis of the potential role of C1858 T as a target for
tertiary prevention trials and new therapeutic strategies, such as the Lyp inhibitors,
they suggested that PTPN22 can be a promising target for therapeutic interventions
and identification of at-risk subjects in autoimmune diseases such as T1DM.
It has been shown that several SNPs could potentially contribute to susceptibility
to various autoimmune disorders including T1DM. However, 1858C/T SNP is the
most stable, where T-allele correlates with T1DM (Table 11) [7, 142, 152, 183]. Habib
et al. [211] demonstrate a role of PTPN22 1858T in signaling defects in both transi-
tional and naïve B cells in healthy subjects resulting in an increased resistance to BCR-
driven apoptosis in these cells and peripheral reservoir of autoreactive cells [212].
14. Systemic sclerosis
SSc is a complex disease with an autoimmune origin in which extensive fibrosis,
vascular alterations, and autoantibodies against various cellular antigens are among
the principal features [213]. Although the etiopathogenesis is not yet well under-
stood, the results of numerous genetic association studies support genetic contribu-
tions as an important factor to SSc.
SSc occurs in persons who are genetically predisposed and have faced specific
environmental factors with or without other randomly distributed factors
[214, 215]. It has been consistently associated with the major histocompatibility
complex variants. Non-HLA genes associated with immunity have also been associ-
ated with SSc susceptibility [214].
In spite of these findings, the complete genetic background of SSc, the nature of
its genetic determinants, and how they contribute to SSc susceptibility and clinical
manifestations are poorly understood. Interestingly, PTPN22 has emerged as an
important genetic risk factor for human autoimmunity. The PTPN22 C1858T poly-
morphism in SSc has also been investigated and shows a trend of association
(Table 12). It has been associated with SSc susceptibility in French [216], Caucasian
[214], andWhite, Black, and Hispanic American [217]. A meta-analysis showed that
PTPN22 1858T is susceptible to SSc [107]. Some other report shows the absence of
any association between this polymorphism and SSc in French [218], Columbian
[87], and Spanish [219].
17
The Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22) Gene Polymorphism…
DOI: http://dx.doi.org/10.5772/intechopen.90836
15. Myasthenia gravis
MG is an antibody-mediated autoimmune disease against antigens at the neuro-
muscular junction. Both genetic and environmental factors contribute to the sus-
ceptibility of MG. The annual incidence of MG is reported to be 0.25–4 patients per
100,000 population, with the first peak of onset around the second and third
decades of life and the second peak around the fifth and sixth decades [220, 221].
The exact mechanism of the autoimmunity in MG is unknown. It is caused mostly
by the autoantibodies directed toward the skeletal muscle acetylcholine receptor
(AChR), but there are cases in which autoimmune attack targets non-AChR com-
ponents of the postsynaptic muscle endplate [222–225]. It has been suggested that
genetic factors might play an important role in the development of MG [226–227].
Some studies showed that PTPN22 C1858T polymorphism is associated with MG
risk (Table 13).
PTPN22 C1858T polymorphism is associated with MG susceptibility in Swedish
[228], German [229], European [230], Hungarian [231], and French patients [232].
However, the association between this polymorphism and the risk of MG was con-
troversial and inconclusive in Chinese, Italian, and Turkish patients [2, 233, 234].
16. Behcet’s diseases
BD is characterized by recurrent orogenital ulcers, cutaneous inflammation, and
uveitis. It is a chronic autoimmune/inflammatory disorder with typical mucocuta-
neous and ocular manifestations. It also targets musculoskeletal, nervous, vascular,
and gastrointestinal systems [236]. The prevalence of BD varies with geographical
locations. It is more prevalent in countries along the silk route, particularly in the
East Asia and the Middle East. Prevalence is highest in Turkey, followed by Egypt,
Morocco, Iraq, Saudi Arabia, Japan, Iran, Korea, and China [237, 238]. Available
reports indicate that autoimmunity, genetic factors, and environmental factors are
involved in the pathogenesis of BD; however, the specific etiology remains to be
determined [236, 239, 240].
Being an autoimmune disease, BD is considered to be affected by PTPN22
C1858T polymorphism. However, there is no significant association of this gene in
susceptibility to BD (Table 14). Baranathan et al. [241] suggested that PTPN22
C1858T is inversely associated with BD in the UK population indicating its protec-
tive role in BD. However, this does not hold for Middle Eastern patients in whom
PTPN22 C1858T expression does not associate with BD, possibly due to a very low
prevalence of the polymorphism in this population.
The prevalence of PTPN22 C1858T is very low in the general population, and the
absence of any correlation with BD indicates that PTPN22 C1858T polymorphism
has a limited role in the pathogenesis of autoimmunity [242]. Recently Ortiz-Fe
rnández [243] also could not find any association of PTPN22 C1858T polymorphism
with BD in Spanish patients.
17. Endometriosis
Endometriosis is a chronic inflammatory disease and one of the most common
benign gynecological disorders. It is a condition in which a tissue that is histologi-
cally similar to the endometrium, with glands and/or stroma, grows outside the
uterine cavity [244]. It presents a multisystem involvement affecting several
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organs, most commonly in the peritoneum and pelvis, especially the ovaries, and
less often in the rectovaginal septum. This results in pelvic pain, dysmenorrhea, and
infertility [245].
Although various hypotheses have been proposed to explain the etiology of
endometriosis, the explanation of symptoms and presence of ectopic endometrial
tissue and stroma at various sites is not very clear [246].
The etiology of endometriosis is complex and characterized by genetic and
environmental factors similar to other autoimmune diseases. The immunological
changes such as an increase in the number and cytotoxicity of macrophages,
increase in the activity of B lymphocytes, abnormalities in the functions and con-
centrations of B and T lymphocytes, and reduction in the number or the activity of
natural killer cells have been indicated in endometriosis. Anti-endometrial and anti-
ovary antibodies have been also found in endometriosis [247]. As genetic factors
and immunological predispositions are involved in the etiology of the disease,
therefore the variants of genes associated with autoimmune diseases are possible
candidates for endometriosis development [247]. PTPN22 C1858T polymorphism
and its association with endometriosis have been studied in only three populations
(Brazilian, Italian, and Polish) so far (Table 15).
The PTPN22 C1858T polymorphism has been reported to be associated with
altered risk of endometriosis in Italian and Brazilian populations, but no significant
association was found in Polish patients. However, on exploratory analyses Płoski
et al. [248] suggested that the T-allele and the TT genotype may be associated with
the prevalence of double positivity for antinuclear antibody (ANA) and anti-
cardiolipin autoantibody (ACA).
A meta-analysis showed overall increased risk associations of up to 5.6-fold in
endometriosis. In the presence of endometriosis, the PTPN22 C1858T polymor-
phism may cooperate with clinical and genetic factors to influence the course of
disease and immune reactions. These cooperative interactions could result in a
statistical association between PTPN22 C1858T and endometriosis [246].
The lymphoid tyrosine phosphatase enzyme is encoded by PTPN22 gene and is a
regulator of signaling through the T-cell receptor and forms a complex with the
kinase Csk in T cells. The variant of PTPN22 C1858T polymorphism does not bind
kinases properly and results in a gain-of-function enzyme [246, 249, 250]. The
increased inhibition of T-cell receptor signaling caused by the PTPN22 C1858T
polymorphism could predispose toward autoimmunity, either by affecting the thy-
mic deletion of autoreactive T cells or by affecting the development or function of
peripheral regulatory T cells [251].
18. Antineutrophil cytoplasmic antibody-associated vasculitis
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an
uncommon inflammatory disease, characterized by inflammation in small- to
medium-sized vessels, necrosis, and association with detectable circulating ANCAs.
Though the manifestations in the lungs and kidneys are common, any organ or
system can be affected. AAV refers to a group of small-vessel vasculitis, including
granulomatosis with polyangiitis (GPA, formerly known as Wegener’s
granulomatosis), microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA,
formerly Churg-Strauss syndrome) [256].
AAV is a complex disease with both genetic and environmental factors involved
in pathogenesis [257]. There is increasing evidence that susceptibility loci are shared
between autoimmune diseases. The candidate gene association studies and the
GWASs have shown the genetic basis of AAV. The significant association of AAV
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with HLA polymorphisms has confirmed the central role of autoimmunity in the
development of AAV. All the three main subtypes mentioned above have been
reported to be associated with distinct HLA variants [258].
The role of PTPN22 C1858T in AAV provided the basis for the three main
PTPN22 genetic association studies performed so far (Table 16). The first, which
included a German cohort, showed an association of this variant with the disease;
the association was even more significant in the ANCA-positive subgroup [259].
This result has been subsequently replicated in two independent cohorts of British
[260] and Italian AAV patients [261]. However, the study on Italian patients
showed that the association is restricted to the GPA patients only, as almost similar
frequency of the T-allele of PTPN22 C1858T was found in the MPA or the EGPA
patients and controls.
Three independent meta-analyses indicated that PTPN22 C1858T polymorphism
is significantly associated with susceptibility of AAV in Caucasian population
[76, 262].
19. Giant cell arteritis
GCA is a form of vasculitis. It is very common in elderly people and may cause
blindness and stroke [263]. The environmental, infectious, and genetic risk factors
have been associated with GCA development; however, the pathogenesis is not
clear yet. PTPN22 is a gene of interest which is proposed to be an “archetypal non-
HLA autoimmunity gene” [251, 264]. The T-allele of a functional PTPN22 C1858T
polymorphism has been reported to be associated with biopsy-proven GCA in
Spanish patients (Table 17), with supporting data from three replicate Northern
European studies [265]. Recently, this observation has been extended with addi-
tional patients and controls and studies encompassing European, Scandinavian, UK,
and American patients [266], though an earlier report from Spanish patients does
not support the potential involvement of PTPN22 gene polymorphism in the sus-
ceptibility or clinical expression of GCA [263].
Though Lester et al. [267] could not find any significant difference in the distri-
bution of alleles and genotypes of PTPN22 C1858T polymorphism between patients
and control groups, they suggested that there is a significant association between
the minor allele of PTPN22 C1858T polymorphism and GCA.
20. Autoimmune Addison’s disease (AAD)
AAD occurs due to autoimmune destruction of the adrenal cortex. Approxi-
mately half of the patients have additional autoimmune components. The preva-
lence of AAD varies from 110 to 144 cases per million in the developed countries. In
adult patients, AAD is the most common etiological form (80%), followed by post-
tuberculosis AD (10–15%) and vascular, neoplastic, or rare genetic forms (5%)
[268]. AAD commonly coexists with thyroid autoimmunity and/or type I diabetes
and is called as autoimmune polyendocrine syndrome type II (APS II).
Several genetic determinants have long been suspected to be involved in various
autoimmune diseases. PTPN22 C1858T polymorphism has been studied in AAD
patients with inconsistent results (Table 18). Velaga et al. [151] reported an associ-
ation for the T-allele in patients from northeast England, whereas Kahles et al. [185]
found no association in German patients. This inconsistency may be due to small
sample size. The 1858T allele is associated with susceptibility to AAD in Norwegians
[269], UK cohort, and the Polish population [270]. Meta-analysis of the results,
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together with those from three other populations, showed that the 1858T allele is
associated with AAD susceptibility.
Confounding factors must be considered particularly when polymorphisms
identified in one study cannot be duplicated in a similar ethnic group. One
confounding factor is population stratification. This may occur with an unbalanced
ethnic admixture.
It is clear that the inheritance of a coding variant of PTPN22 gene is associated
with increased susceptibility to autoimmunity. The mechanism by which the
PTPN22 C1858T variant modulates disease risk has been studied. PTPN22 is capable
of both enzymatic activities and adaptor functions. It exerts its effects in multiple
biochemical pathways and cell types. PTPN22 regulates signaling through both
antigen and innate immune receptors. It is involved in the development and acti-
vation of lymphocyte, establishment of tolerance, and innate immune cell-mediated
host defense and immunoregulation. The PTPN22 C1858T variant protein is
involved in the pathogenesis of autoimmunity at multiple levels. The action of
PTPN22 C1858T during immature B-cell selection disrupts the establishment of a
tolerant B-cell repertoire and alters mature T-cell responsiveness. When an auto-
immune attack initiates tissue injury, the TPN22C1858T fosters inflammation by
regulating the level of cytokines produced by a myeloid cell.
21. Conclusion
The PTPN22 C1858T is one of the strongest and most consistent genetic associ-
ations with autoimmune diseases. However, available literature on PTPN22 C1858T
polymorphism and autoimmune diseases shows ethnic variations. It is conceivable
that the relation of any locus with the autoimmune disease will be small as interac-
tions between gene and gene and gene and environment might also be operating.
Further well-designed studies from different populations and cohorts to detect
small genetic risk will help in drawing better conclusion on the development of
autoimmune diseases. Therefore, further genetic studies on patients suffering from
various autoimmune diseases from different ethnicities and PTPN22 gene polymor-
phisms are expected to help better understand the pathogenesis and will contribute
to the development of more targeted therapies and biomarkers.
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